You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Hydrochlorothiazide; quinapril hydrochloride - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for hydrochlorothiazide; quinapril hydrochloride and what is the scope of freedom to operate?

Hydrochlorothiazide; quinapril hydrochloride is the generic ingredient in two branded drugs marketed by Pfizer Pharms, Apotex, Aurobindo Pharma, Chartwell Rx, Invagen Pharms, Norvium Bioscience, and Sun Pharm Inds Ltd, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound.

Summary for hydrochlorothiazide; quinapril hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Patent Applications:	1
DailyMed Link:	hydrochlorothiazide; quinapril hydrochloride at DailyMed

Recent Clinical Trials for hydrochlorothiazide; quinapril hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
LaborMed Pharma S.A.	Phase 4
National Center for Research Resources (NCRR)	Phase 4
Vanderbilt University Medical Center	Phase 4

See all hydrochlorothiazide; quinapril hydrochloride clinical trials

Pharmacology for hydrochlorothiazide; quinapril hydrochloride

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; quinapril hydrochloride

US Patents and Regulatory Information for hydrochlorothiazide; quinapril hydrochloride

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Invagen Pharms	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	201356-003	Apr 20, 2011		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Invagen Pharms	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	201356-002	Apr 20, 2011		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Apotex	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	091524-001	Mar 12, 2013	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Sun Pharm Inds Ltd	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	078211-003	Mar 4, 2009		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for hydrochlorothiazide; quinapril hydrochloride

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-003	Dec 28, 1999	⤷ Subscribe	⤷ Subscribe
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-001	Dec 28, 1999	⤷ Subscribe	⤷ Subscribe
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-003	Dec 28, 1999	⤷ Subscribe	⤷ Subscribe
Pfizer Pharms	ACCURETIC	hydrochlorothiazide; quinapril hydrochloride	TABLET;ORAL	020125-002	Dec 28, 1999	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Hydrochlorothiazide; quinapril hydrochloride Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Hydrochlorothiazide and Quinapril Hydrochloride

Introduction to Hydrochlorothiazide and Quinapril Hydrochloride

Hydrochlorothiazide and quinapril hydrochloride are commonly used in combination to treat hypertension, a condition that affects a significant portion of the global population. Hydrochlorothiazide is a diuretic that reduces blood pressure by increasing urine flow, while quinapril is an angiotensin-converting enzyme (ACE) inhibitor that relaxes blood vessels to lower blood pressure[4].

Global Market Size and Growth

The global antihypertensive drugs market, which includes medications like hydrochlorothiazide and quinapril, was valued at USD 22.60 billion in 2023 and is projected to reach USD 33.49 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 3.87% during the forecast period[1].

Key Drivers of Market Growth

Increasing Incidence of Hypertension

The rising prevalence of hypertension worldwide is a significant driver of the market. According to the World Health Organization (WHO), approximately 1.13 billion people suffer from hypertension globally, and this number is expected to increase to 29% by 2025, particularly in economically developing nations[3].

Aging Population

The global population is aging, and this demographic shift is contributing to an increase in hypertension cases. Elderly patients are more likely to have age-related heart, kidney, or liver problems, which necessitate the use of antihypertensive medications[4].

Public Awareness and Health Campaigns

Growing public awareness of cardiovascular diseases and public health campaigns highlighting the risks of uncontrolled hypertension are driving the demand for efficient antihypertensive medications[1].

Healthcare Expenditure and R&D Activities

Increased healthcare expenditure and research & development activities by pharmaceutical companies are also propelling the market growth. New product launches and the development of novel drugs are expected to further boost the market[3].

Market Segmentation

Drug Class Segment

Diuretics, such as hydrochlorothiazide, dominate the drug class segment due to their established and cost-effective nature as a first-line treatment for hypertension. They are often included in combination therapy, which enhances their market presence[1].

Distribution Channel Segment

Hospital pharmacies dominate the distribution channel segment because they stock a wider range of medications, including specialized and investigational drugs. This is particularly important for patients requiring closer monitoring or specific treatment plans[1].

Regional Market Dynamics

North America

North America is the largest market shareholder for antihypertensive drugs, driven by the demand for rapid and precise hypertension diagnosis and treatment, advanced healthcare facilities, and the need to manage the prognosis of the condition[1].

Asia Pacific

The Asia Pacific region is the fastest-growing market, fueled by a large and growing population with high hypertension rates, especially in China and India. An aging population and rising heart disease rates in this region further drive the demand for antihypertensive medications[1].

Challenges and Restraints

Product Recalls

Product recalls, such as the recall of ACCURETIC (quinapril HCl/hydrochlorothiazide) by Pfizer Inc. in March 2022 due to elevated levels of a potentially cancer-causing impurity, can hinder market growth. These recalls can reduce patient confidence and reluctance to begin or continue taking their prescribed medications[1].

Side Effects

Side effects associated with hydrochlorothiazide, such as electrolyte imbalances and increased risk of certain infections, can also hamper the growth of the market[3].

Strategic Approaches for Market Success

Focus on Generics

Focusing on generic medications can increase affordability and accessibility for patients in cost-conscious areas. Generic versions of hydrochlorothiazide and quinapril can help expand market reach and improve public health outcomes[1].

Strategic Launches

Strategic launches, particularly those targeting underserved areas and leveraging partnerships with local healthcare professionals, can enhance market penetration and ensure more patients have access to efficient treatments[1].

Financial Trajectory

The financial trajectory of the antihypertensive drugs market, including hydrochlorothiazide and quinapril, is positive due to the confluence of driving factors. Here are some key financial metrics:

Base Year Market Size: USD 22.60 billion in 2023
Forecast Year Market Size: USD 33.49 billion by 2032
CAGR: 3.87% during the forecast period (2024-2032)[1].

Key Takeaways

The global antihypertensive drugs market is driven by increasing hypertension incidence, an aging population, and growing public awareness.
Diuretics like hydrochlorothiazide dominate the market due to their cost-effectiveness and rapid blood pressure-lowering effect.
North America and the Asia Pacific are key regions driving market growth.
Product recalls and side effects are significant challenges that need to be addressed.
Focusing on generics and strategic launches are crucial strategies for market success.

Frequently Asked Questions (FAQs)

Q: What is the primary use of hydrochlorothiazide and quinapril in combination? A: The combination of hydrochlorothiazide and quinapril is used to treat high blood pressure (hypertension) by reducing blood pressure and increasing the supply of blood and oxygen to the heart[4].

Q: What are the key drivers of the antihypertensive drugs market? A: The key drivers include the increasing incidence of hypertension, an aging population, growing public awareness of cardiovascular diseases, and increased healthcare expenditure[1][3].

Q: Which region is expected to be the fastest-growing market for antihypertensive drugs? A: The Asia Pacific region is expected to be the fastest-growing market, driven by a large and growing population with high hypertension rates, especially in China and India[1].

Q: What are the potential challenges facing the antihypertensive drugs market? A: Product recalls and side effects associated with medications like hydrochlorothiazide are significant challenges that can hinder market growth[1][3].

Q: How can pharmaceutical companies successfully navigate the global antihypertensive market? A: Focusing on generics and making strategic launches, particularly in underserved areas and through partnerships with local healthcare professionals, can help companies successfully navigate the market[1].

Cited Sources:

Straits Research - Global Antihypertensive Drugs Market Size, Top Share, Forecast to 2032
Pfizer Medical Information - ACCURETIC® Dosage and Administration
Allied Market Research - Hydrochlorothiazide Market Size | Industry Growth, (2021-2030)
Mayo Clinic - Quinapril and hydrochlorothiazide (oral route)
VA Formulary Advisor - HYDROCHLOROTHIAZIDE/ QUINAPRIL TAB

More… ↓

⤷ Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.